Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.

about

P2860

Q47566809-59E6C208-B681-4313-904E-EB6BB3FBA0A2

P2860

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q38839812

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment-related adverse even ...... acute lymphoblastic leukemia.

@en

type

Item

label

Treatment-related adverse even ...... acute lymphoblastic leukemia.

@en

prefLabel

Treatment-related adverse even ...... acute lymphoblastic leukemia.

@en

P1476

Treatment-related adverse even ...... acute lymphoblastic leukemia.

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Alison Smith

http://www.w3.org/2001/XMLSchema#string

Jemily Malvar

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wilkes

http://www.w3.org/2001/XMLSchema#string

Jill Hoffman

http://www.w3.org/2001/XMLSchema#string

Michael J Burke

http://www.w3.org/2001/XMLSchema#string

Minjun Hur

http://www.w3.org/2001/XMLSchema#string

Rebecca Gardner

http://www.w3.org/2001/XMLSchema#string

Richard Sposto

http://www.w3.org/2001/XMLSchema#string

Susan R Rheingold

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance

Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia.

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analys

P304

1943-1948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.26129

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Etan Orgel

P577

2016-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27437864

http://www.w3.org/2001/XMLSchema#string

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.

about

P2860

P2860

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698